Chemoinformaics analysis of (+/-)-6-acetonyldihydrosanguinarine
| Molecular Weight | 389.407 | nRot | 2 |
| Heavy Atom Molecular Weight | 370.255 | nRig | 30 |
| Exact Molecular Weight | 389.126 | nRing | 6 |
| Solubility: LogS | -7.233 | nHRing | 3 |
| Solubility: LogP | 4.684 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 48 | No. of Aliphatic Hetero Cycles | 3 |
| No. of Heavy Atom | 29 | No. of Aromatic Carbocycles | 3 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 19 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 23 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 16 |
| No. of Oxygen atom | 5 | No. of Arom Bond | 17 |
| nHA | 6 | APOL | 56.1891 |
| nHD | 0 | BPOL | 28.5829 |
| QED | 0.646 |
| Synth | 3.424 |
| Natural Product Likeliness | 1.197 |
| NR-PPAR-gamma | 0.025 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.011 |
| Pgp-sub | 0.38 |
| HIA | 0.002 |
| CACO-2 | -4.815 |
| MDCK | 0.000043 |
| BBB | 0.089 |
| PPB | 0.979403 |
| VDSS | 0.482 |
| FU | 0.0119388 |
| CYP1A2-inh | 0.979 |
| CYP1A2-sub | 0.198 |
| CYP2c19-inh | 0.983 |
| CYP2c19-sub | 0.273 |
| CYP2c9-inh | 0.861 |
| CYP2c9-sub | 0.935 |
| CYP2d6-inh | 0.981 |
| CYP2d6-sub | 0.93 |
| CYP3a4-inh | 0.941 |
| CYP3a4-sub | 0.366 |
| CL | 15.75 |
| T12 | 0.116 |
| hERG | 0.044 |
| Ames | 0.843 |
| ROA | 0.162 |
| SkinSen | 0.391 |
| Carcinogencity | 0.962 |
| EI | 0.036 |
| Respiratory | 0.907 |
| NR-Aromatase | 0.457 |
| Antiviral | Yes |
| Prediction | 0.701644 |